EP3273993A4 - Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer - Google Patents

Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer Download PDF

Info

Publication number
EP3273993A4
EP3273993A4 EP16773863.2A EP16773863A EP3273993A4 EP 3273993 A4 EP3273993 A4 EP 3273993A4 EP 16773863 A EP16773863 A EP 16773863A EP 3273993 A4 EP3273993 A4 EP 3273993A4
Authority
EP
European Patent Office
Prior art keywords
cancer
cells
treatment
monoclonal antibodies
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16773863.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3273993A2 (en
Inventor
Tien Lee
Hans G. KLINGEMANN
Barry J. SIMON
Laurent BOISSEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
NantKwest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57006343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3273993(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NantKwest Inc filed Critical NantKwest Inc
Publication of EP3273993A2 publication Critical patent/EP3273993A2/en
Publication of EP3273993A4 publication Critical patent/EP3273993A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP16773863.2A 2015-03-27 2016-03-25 Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer Pending EP3273993A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562139258P 2015-03-27 2015-03-27
PCT/US2016/024318 WO2016160602A2 (en) 2015-03-27 2016-03-25 Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer

Publications (2)

Publication Number Publication Date
EP3273993A2 EP3273993A2 (en) 2018-01-31
EP3273993A4 true EP3273993A4 (en) 2018-11-07

Family

ID=57006343

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16773863.2A Pending EP3273993A4 (en) 2015-03-27 2016-03-25 Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer

Country Status (10)

Country Link
US (6) US10456420B2 (enExample)
EP (1) EP3273993A4 (enExample)
JP (5) JP6748105B2 (enExample)
KR (3) KR102460387B1 (enExample)
CN (4) CN114533867A (enExample)
AU (3) AU2016243120B2 (enExample)
CA (1) CA2977423A1 (enExample)
HK (2) HK1247117A1 (enExample)
IL (4) IL294982B2 (enExample)
WO (1) WO2016160602A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3273993A4 (en) 2015-03-27 2018-11-07 Nantkwest, Inc. Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
JP7178906B2 (ja) 2016-05-19 2022-11-28 ザ ジェネラル ホスピタル コーポレイション ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２
CA3042238C (en) * 2016-10-28 2021-08-10 Nant Holdings Ip, Llc Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death
US20180221463A1 (en) * 2017-01-13 2018-08-09 The Chinese University Of Hong Kong Modified NK Cells and Uses Thereof
CN110418839B (zh) * 2017-03-08 2023-06-09 免疫生物公司 用于临床的修饰的NK-92haNK003细胞
CA3128202A1 (en) * 2017-05-11 2018-11-15 Nantkwest, Inc. Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment
WO2019201629A1 (en) * 2018-04-19 2019-10-24 Onkimmune Limited Nk cells for use with antibodies in cancer therapy
CN108531458A (zh) * 2018-04-27 2018-09-14 赛诺（深圳）生物医药研究有限公司 治疗肿瘤的基因工程自然杀伤细胞产品
WO2020014245A1 (en) 2018-07-10 2020-01-16 Nantkwest, Inc. Cryopreservation
JP7241161B2 (ja) 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
CN118976120A (zh) * 2018-09-07 2024-11-19 南特生物公司 刺激hank和nk92mi细胞的靶向il-12治疗和方法
CA3092709A1 (en) 2018-10-31 2020-05-07 Nantkwest, Inc. Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells
KR102533540B1 (ko) * 2018-10-31 2023-05-17 난트퀘스트, 인크. Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거(elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells)
CA3117936A1 (en) * 2018-11-26 2020-06-04 Immunitybio, Inc. Il-2 dependent nk-92 cells with stable fc receptor expression
CN119040363A (zh) 2019-03-15 2024-11-29 河谷细胞有限公司 重组erIL-15 NK细胞
US12085571B2 (en) 2019-06-13 2024-09-10 Immunitybio, Inc. Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags
JP7555392B2 (ja) * 2019-07-26 2024-09-24 ナントクウェスト，インコーポレーテッド 腫瘍溶解のための有効な治療用製剤としての、抗体を予め負荷したｃｄ１６＋ｎｋ－９２細胞
US11992504B2 (en) * 2019-11-20 2024-05-28 Immunitybio, Inc. Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
CA3208717A1 (en) * 2021-02-19 2022-08-25 Preet M. Chaudhary Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
CN116948012B (zh) * 2022-04-13 2024-07-26 星奕昂(上海)生物科技有限公司 增强细胞功能的cd16抗剪切突变体
WO2024064824A2 (en) 2022-09-21 2024-03-28 Yale University Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
WO2025158400A1 (en) 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy
US20250298030A1 (en) * 2024-03-20 2025-09-25 Immunitybio, Inc. Compositions and Methods for NK-92 Cells Expressing Native CD16

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060029583A1 (en) * 2004-07-02 2006-02-09 Sirac Dilber Method for the genetic activation of cells and uses of said cells
US20060292156A1 (en) * 2004-07-10 2006-12-28 Campbell Kerry S Genetically modified human natural killer cell lines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1172981A3 (en) * 2000-07-10 2006-11-15 Broadcom Corporation Analogue front end for xDSL
ATE483472T1 (de) * 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
KR102360693B1 (ko) * 2014-07-11 2022-02-08 벤타나 메디컬 시스템즈, 인코포레이티드 항-pd-l1 항체 및 이의 진단 용도
US9078488B1 (en) * 2014-09-30 2015-07-14 Nike, Inc. Article of footwear incorporating a lenticular knit structure
EP3273993A4 (en) * 2015-03-27 2018-11-07 Nantkwest, Inc. Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060029583A1 (en) * 2004-07-02 2006-02-09 Sirac Dilber Method for the genetic activation of cells and uses of said cells
US20060292156A1 (en) * 2004-07-10 2006-12-28 Campbell Kerry S Genetically modified human natural killer cell lines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B�ATRICE CL�MENCEAU ET AL: "In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2015, 22 October 2015 (2015-10-22), pages 1 - 13, XP055511040, ISSN: 2314-8861, DOI: 10.1155/2015/482089 *
BOISSEL L ET AL: "NK-92: AN 'OFF THE SHELF' TARGET-SPECIFIC CYTOTOXIC CELL THERAPEUTIC", CYTOTHERAPY, & 21ST ANNUAL MEETING OF THE INTERNATIONAL-SOCIETY-FOR-CELLULAR-THERAPY (ISCT); LAS VEGAS, NV, USA; MAY 27 -27, 2015, vol. 17, no. 6, Suppl. S, S19, 1 June 2015 (2015-06-01), pages 44, XP002784524 *
KARIN C STRAATHOF ET AL: "A inducible caspase 9 safety switch for T-cell therapy", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 105, no. 11, 1 June 2005 (2005-06-01), pages 4247 - 4254, XP008126232, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2004-11-4564 *
L. BINYAMIN ET AL: "Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy", THE JOURNAL OF IMMUNOLOGY, vol. 180, no. 9, 1 May 2008 (2008-05-01), US, pages 6392 - 6401, XP055248029, ISSN: 0022-1767, DOI: 10.4049/jimmunol.180.9.6392 *

Also Published As

Publication number Publication date
AU2016243120B2 (en) 2021-09-30
US20190365816A1 (en) 2019-12-05
US20210236550A1 (en) 2021-08-05
AU2021266225B2 (en) 2025-01-30
US20180193383A1 (en) 2018-07-12
IL294982A (en) 2022-09-01
KR102460387B1 (ko) 2022-10-28
WO2016160602A9 (en) 2016-11-24
WO2016160602A2 (en) 2016-10-06
IL287051B (en) 2022-09-01
US20200306312A1 (en) 2020-10-01
JP7766151B2 (ja) 2025-11-07
JP6748105B2 (ja) 2020-08-26
JP7000512B2 (ja) 2022-02-10
JP2024164223A (ja) 2024-11-26
KR20250009013A (ko) 2025-01-16
CN117379460A (zh) 2024-01-12
JP7557704B2 (ja) 2024-09-30
US20250340664A1 (en) 2025-11-06
AU2021266225A1 (en) 2021-12-16
IL254214B2 (en) 2024-04-01
IL287051A (en) 2021-12-01
US10456420B2 (en) 2019-10-29
AU2025202587A1 (en) 2025-05-01
AU2016243120A1 (en) 2017-09-07
US11207350B2 (en) 2021-12-28
IL301331A (en) 2023-05-01
KR102751730B1 (ko) 2025-01-10
CN107427578A (zh) 2017-12-01
US11000550B2 (en) 2021-05-11
IL294982B2 (en) 2023-08-01
US20220062343A1 (en) 2022-03-03
JP2018510881A (ja) 2018-04-19
CN113604435A (zh) 2021-11-05
IL254214B1 (en) 2023-12-01
CN114533867A (zh) 2022-05-27
US12384852B2 (en) 2025-08-12
HK1247117A1 (zh) 2018-09-21
JP2022037182A (ja) 2022-03-08
JP2023139298A (ja) 2023-10-03
EP3273993A2 (en) 2018-01-31
IL294982B1 (en) 2023-04-01
US10736921B2 (en) 2020-08-11
HK1249854A1 (zh) 2018-11-16
IL254214A0 (en) 2017-10-31
CA2977423A1 (en) 2016-10-06
KR20220145929A (ko) 2022-10-31
JP7328314B2 (ja) 2023-08-16
JP2020186255A (ja) 2020-11-19
KR20170131569A (ko) 2017-11-29

Similar Documents

Publication Publication Date Title
IL294982B1 (en) nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment
EP3244926B8 (en) Treatment of cancer with anti-lap monoclonal antibodies
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
IL276515B2 (en) PD–L1-specific antibodies and methods of using them
EP3565844B8 (en) Methods of treating cancer with anti-pd-1 antibodies
IL260474B (en) Antibodies specific to cadherin-17 and cytotoxic cells for cancer treatment
HUE053452T2 (hu) Anti-PD-1 és anti-LAG3 antitestek rák kezelésére
EP3273976A4 (en) Modified t cells and methods of making and using the same
NZ731467A (en) Anti-tim3 antibodies and methods of use
DK3142751T3 (da) Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer
EP3645040A4 (en) USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
IL285122A (en) Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
EP3285805A4 (en) Therapeutic antibodies and uses thereof
EP3303402A4 (en) ANTIBODIES TO GLYPICAN-3 AND ITS USE TO CANCER DIAGNOSIS AND TREATMENT
EP3193913A4 (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
EP3209686A4 (en) Monoclonal anti-gpc-1 antibodies and uses thereof
EP3256157A4 (en) Anti-kir antibodies
EP3227681A4 (en) Anti-acetaminophen antibodies and acetaminophen protein adducts
HK40104789A (zh) 用於治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体
HK40122787A (zh) 治疗性抗体和它们的用途
HK40119074A (zh) 用於癌症诊断的抗体
HK40003120A (en) Anti-siglec-7 antibodies for the treatment of cancer
HK40016654A (en) Methods of treating cancer with anti-tim-3 antibodies
HK40034991A (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
HK40036702A (en) Anti-trem2 antibodies and related methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171020

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181010

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0783 20100101ALI20181004BHEP

Ipc: A61K 35/17 20150101ALI20181004BHEP

Ipc: C07K 16/32 20060101ALI20181004BHEP

Ipc: A61K 39/395 20060101AFI20181004BHEP

Ipc: C07K 16/28 20060101ALI20181004BHEP

Ipc: A61P 35/00 20060101ALI20181004BHEP

Ipc: A61K 38/16 20060101ALI20181004BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1249854

Country of ref document: HK

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUNITYBIO, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CAMPBELL, KERRY

Inventor name: BOISSEL, LAURENT

Inventor name: SIMON, BARRY J.

Inventor name: KLINGEMANN, HANS G.

Inventor name: LEE, TIEN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250528